Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment – a nationwide cohort study
Von Automat
-
Real-world efficacy of biologics may be insufficiently assessed through common drug survival studies. The objective was thus to examine real-world …